Effects of 3-butenyl isothiocyanate on phenotypically different prostate cancer cells
- Authors:
- M.j. Núñez-Iglesias
- S. Novio
- C. García-Santiago
- M.e. Cartea
- P. Soengas
- P. Velasco
- M. Freire-Garabal
-
Affiliations: Screening of New Libraries Laboratory, School of Medicine and Dentistry, University of Santiago de Compostela, 15782 A Coruña, Spain, Group of Genetics, Breeding and Biochemistry of Brassicas, Biological Mission of Galicia, CSIC, 36143 Pontevedra, Spain - Published online on: August 29, 2018 https://doi.org/10.3892/ijo.2018.4545
- Pages: 2213-2223
This article is mentioned in:
Abstract
 |
 |
 |
 |
 |
 |
 |
 |
|
Zhou CK, Check DP, Lortet-Tieulent J, Laversanne M, Jemal A, Ferlay J, Bray F, Cook MB and Devesa SS: Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group. Int J Cancer. 138:1388–1400. 2016. View Article : Google Scholar : | |
|
Mitchell S, Abel P, Ware M, Stamp G and Lalani E: Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int. 85:932–944. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Spiotto MT and Chung TD: STAT3 mediates IL-6-induced neuro-endocrine differentiation in prostate cancer cells. Prostate. 42:186–195. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D and Rédini F: DU145 human prostate cancer cells express functional receptor activator of NFkappaB: New insights in the prostate cancer bone metastasis process. Bone. 40:981–990. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
van Duijn PW and Trapman J: PI3K/Akt signaling regulates p27(kip1) expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27(kip1) regulation in LNCaP and PC346 cells. Prostate. 66:749–760. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Proverbs-Singh T, Feldman JL, Morris MJ, Autio KA and Traina TA: Targeting the androgen receptor in prostate and breast cancer: Several new agents in development. Endocr Relat Cancer. 22:R87–R106. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PCA, Carducci MA, Monk JP, et al: Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): A randomised phase 3 trial. Lancet Oncol. 14:893–900. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y and Pouliot F: Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy. Eur Urol Focus. 3:639–642. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Katzenwadel A and Wolf P: Androgen deprivation of prostate cancer: Leading to a therapeutic dead end. Cancer Lett. 367:12–17. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, et al: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): A randomised, open-label, phase 3 trial. Lancet Oncol. 14:149–158. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, et al: Management of patients with advanced prostate cancer: Recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 26:1589–1604. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Ohlmann CH, Goebell PJ, Grimm MO, Klier J, König F, Machtens S, Schostak M, Schrader AJ and Albers P: Metastatic prostate cancer: Update: position paper for the use of chemotherapy. Urologe A. 56:1597–1602. 2017.In German. View Article : Google Scholar : PubMed/NCBI | |
|
Oudard S, Fizazi K, Sengeløv L, Daugaard G, Saad F, Hansen S, Hjälm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, et al: Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial-FIRSTANA. J Clin Oncol. 35:3189–3197. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Galsky MD and Vogelzang NJ: Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol. 21:2135–2144. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Pitcher B, Khoja L, Hamilton RJ, Abdallah K, Pintilie M and Joshua AM: Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS). PLoS One. 12:e01705442017. View Article : Google Scholar : PubMed/NCBI | |
|
Hwang C: Overcoming docetaxel resistance in prostate cancer: A perspective review. Ther Adv Med Oncol. 4:329–340. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG and de Bono JS: Prostate cancer. Lancet. 387:70–82. 2016. View Article : Google Scholar | |
|
Mouhid L, Corzo-Martínez M, Torres C, Vázquez L, Reglero G, Fornari T and Ramírez de Molina A: Improving in vivo efficacy of bioactive molecules: An overview of potentially antitumor phytochemicals and currently available lipid-based delivery systems. J Oncol. 2017:73519762017. View Article : Google Scholar : | |
|
Tummala R, Lou W, Gao AC and Nadiminty N: Quercetin targets hnRNPA1 to overcome enzalutamide resistance in prostate cancer cells. Mol Cancer Ther. 16:2770–2779. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y and Talalay P: Anticarcinogenic activities of organic isothiocyanates: Chemistry and mechanisms. Cancer Res. 54 (Suppl 7): 1976s–1981s. 1994.PubMed/NCBI | |
|
Zhao B, Seow A, Lee EJ, Poh WT, Teh M, Eng P, Wang YT, Tan WC, Yu MC and Lee HP: Dietary isothiocyanates, glutathione S-transferase -M1, -T1 polymorphisms and lung cancer risk among Chinese women in Singapore. Cancer Epidemiol Biomarkers Prev. 10:1063–1067. 2001. | |
|
Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y and Shields PG: Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr. 134:1134–1138. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Halkier BA and Gershenzon J: Biology and biochemistry of glucosinolates. Annu Rev Plant Biol. 57:303–333. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Z, Smith TJ, Wang E, Eklind KI, Chung FL and Yang CS: Structure-activity relationships of arylalkyl isothiocyanates for the inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolism and the modulation of xenobiotic-metabolizing enzymes in rats and mice. Carcinogenesis. 14:1167–1173. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Rampal G, Thind TS, Arora R, Vig AP and Arora S: Synergistic antimutagenic effect of isothiocyanates against varied mutagens. Food Chem Toxicol. 109:879–887. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Papi A, Orlandi M, Bartolini G, Barillari J, Iori R, Paolini M, Ferroni F, Grazia Fumo M, Pedulli GF and Valgimigli L: Cytotoxic and antioxidant activity of 4-methylthio-3-butenyl isothiocyanate from Raphanus sativus L. (Kaiware Daikon) sprouts. J Agric Food Chem. 56:875–883. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung KL and Kong AN: Molecular targets of dietary phenethyl isothiocyanate and sulforaphane for cancer chemoprevention. AAPS J. 12:87–97. 2010. View Article : Google Scholar : | |
|
Wu CL, Huang AC, Yang JS, Liao CL, Lu HF, Chou ST, Ma CY, Hsia TC, Ko YC and Chung JG: Benzyl isothiocyanate (BITC) and phenethyl isothiocyanate (PEITC)-mediated generation of reactive oxygen species causes cell cycle arrest and induces apoptosis via activation of caspase-3, mitochondria dysfunction and nitric oxide (NO) in human osteogenic sarcoma U-2 OS cells. J Orthop Res. 29:1199–1209. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kadir NH, David R, Rossiter JT and Gooderham NJ: The selective cytotoxicity of the alkenyl glucosinolate hydrolysis products and their presence in Brassica vegetables. Toxicology. 334:59–71. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Arora R, Kumar R, Mahajan J, Vig AP, Singh B, Singh B and Arora S: 3-Butenyl isothiocyanate: A hydrolytic product of glucosinolate as a potential cytotoxic agent against human cancer cell lines. J Food Sci Technol. 53:3437–3445. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Okamura T, Umemura T, Inoue T, Tasaki M, Ishii Y, Nakamura Y, Park EY, Sato K, Matsuo T, Okamoto S, et al: Chemopreventive effects of 4-methylthio-3-butenyl Isothiocyanate (Raphasatin) but not curcumin against pancreatic carcinogenesis in hamsters. J Agric Food Chem. 61:2103–2108. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Suzuki I, Cho YM, Hirata T, Toyoda T, Akagi JI, Nakamura Y, Sasaki A, Nakamura T, Okamoto S, Shirota K, et al: Toxic effects of 4-methylthio-3-butenyl isothiocyanate (Raphasatin) in the rat urinary bladder without genotoxicity. J Appl Toxicol. 37:485–494. 2017. View Article : Google Scholar | |
|
Novío S, Cartea ME, Soengas P, Freire-Garabal M and Núñez-Iglesias MJ: Effects of Brassicaceae isothiocyanates on prostate cancer. Molecules. 21:E6262016. View Article : Google Scholar : PubMed/NCBI | |
|
Padilla G, Cartea ME, Velasco P, de Haro A and Ordás A: Variation of glucosinolates in vegetable crops of Brassica rapa. Phytochemistry. 68:536–545. 2007. View Article : Google Scholar | |
|
Smith TK, Lund EK, Clarke RG, Bennett RN and Johnson IT: Effects of Brussels sprout juice on the cell cycle and adhesion of human colorectal carcinoma cells (HT29) in vitro. J Agric Food Chem. 53:3895–3901. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao D, Choi S, Johnson DE, Vogel VG, Johnson CS, Trump DL, Lee YJ and Singh SV: Diallyl trisulfide-induced apoptosis in human prostate cancer cells involves c-Jun N-terminal kinase and extracellular-signal regulated kinase-mediated phosphorylation of Bcl-2. Oncogene. 23:5594–5606. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao D, Vogel V and Singh SV: Benzyl isothiocyanate-induced apoptosis in human breast cancer cells is initiated by reactive oxygen species and regulated by Bax and Bak. Mol Cancer Ther. 5:2931–2945. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Mao L, Yang C, Wang J, Li W, Wen R, Chen J and Zheng J: SATB1 is overexpressed in metastatic prostate cancer and promotes prostate cancer cell growth and invasion. J Transl Med. 11:1112013. View Article : Google Scholar : PubMed/NCBI | |
|
da Silva Ferreira R, Zhou D, Gasperazzo J, Cabral MC, Silva-Lucca RA, Mentele R, Paredes-Gamero EJ, Bertolin TC, dos Santos MT, Guedes PM, et al: Crystal structure of Crataeva tapia bark protein (CrataBL) and its effect in human prostate cancer cell lines. PLoS One. 8:e644262013. View Article : Google Scholar | |
|
Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou V, Huang S and Hong WK: Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/ Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: An effective therapeutic strategy for lung cancer. Clin Cancer Res. 11:6065–6074. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Fimognari C, Nüsse M, Iori R, Cantelli-Forti G and Hrelia P: The new isothiocyanate 4-(methylthio)butylisothiocyanate selectively affects cell-cycle progression and apoptosis induction of human leukemia cells. Invest New Drugs. 22:119–129. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Barillari J, Iori R, Papi A, Orlandi M, Bartolini G, Gabbanini S, Pedulli GF and Valgimigli L: Kaiware Daikon (Raphanus sativus L.) extract: A naturally multipotent chemopreventive agent. J Agric Food Chem. 56:7823–7830. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Papi A, Farabegoli F, Iori R, Orlandi M, De Nicola GR, Bagatta M, Angelino D, Gennari L and Ninfali P: Vitexin-2-O-xyloside, raphasatin and (-)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells. Food Chem. 138:1521–1530. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y, Yao S and Li J: Vegetable-derived isothiocyanates: Anti-proliferative activity and mechanism of action. Proc Nutr Soc. 65:68–75. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y: The molecular basis that unifies the metabolism, cellular uptake and chemopreventive activities of dietary isothiocyanates. Carcinogenesis. 33:2–9. 2012. View Article : Google Scholar : | |
|
Wang N, Wang W, Huo P, Liu CQ, Jin JC and Shen LQ: Mitochondria-mediated apoptosis in human lung cancer A549 cells by 4-methylsulfinyl-3-butenyl isothiocyanate from radish seeds. Asian Pac J Cancer Prev. 15:2133–2139. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Daja MM, Niu X, Zhao Z, Brown JM and Russell PJ: Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines. Prostate Cancer Prostatic Dis. 6:15–26. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tai S, Sun Y, Squires JM, Zhang H, Oh WK, Liang CZ and Huang J: PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate. 71:1668–1679. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Stanton RA, Gernert KM, Nettles JH and Aneja R: Drugs that target dynamic microtubules: A new molecular perspective. Med Res Rev. 31:443–481. 2011. View Article : Google Scholar : | |
|
Mi L, Xiao Z, Hood BL, Dakshanamurthy S, Wang X, Govind S, Conrads TP, Veenstra TD and Chung FL: Covalent binding to tubulin by isothiocyanates. A mechanism of cell growth arrest and apoptosis. J Biol Chem. 283:22136–22146. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Mi L, Gan N, Cheema A, Dakshanamurthy S, Wang X, Yang DC and Chung FL: Cancer preventive isothiocyanates induce selective degradation of cellular alpha- and beta-tubulins by proteasomes. J Biol Chem. 284:17039–17051. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao Z, Mi L, Chung FL and Veenstra TD: Proteomic analysis of covalent modifications of tubulins by isothiocyanates. J Nutr. 142:1377S–1381S. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Magadoux L, Isambert N, Plenchette S, Jeannin JF and Laurens V: Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review). Int J Oncol. 45:919–928. 2014.review. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM and Kyprianou N: Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70:7992–8002. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Khurana N, Talwar S, Chandra PK, Sharma P, Abdel-Mageed AB, Mondal D and Sikka SC: Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells. Int J Oncol. 49:1609–1619. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SH and Singh SV: D, L-Sulforaphane causes transcriptional repression of androgen receptor in human prostate cancer cells. Mol Cancer Ther. 8:1946–1954. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lane DP: Cancer p53, guardian of the genome. Nature. 358:15–16. 1992. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou M, Gu L, Li F, Zhu Y, Woods WG and Findley HW: DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther. 303:124–131. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM and Jenkins RB: Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod Pathol. 15:35–44. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A and Blandino G: Mutant p53: An oncogenic transcription factor. Oncogene. 26:2212–2219. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Gan L, Wang J, Xu H and Yang X: Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling. Prostate. 71:1158–1166. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW and Gao AC: Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate. 73:418–427. 2013. View Article : Google Scholar | |
|
Muller PA and Vousden KH: p53 mutations in cancer. Nat Cell Biol. 15:2–8. 2013. View Article : Google Scholar | |
|
Conley-LaComb MK, Saliganan A, Kandagatla P, Chen YQ, Cher ML and Chinni SR: PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/ CXCR4 signaling. Mol Cancer. 12:852013. View Article : Google Scholar | |
|
Guan X: Cancer metastases: Challenges and opportunities. Acta Pharm Sin B. 5:402–418. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wells A, Yates C and Shepard CR: E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 25:621–628. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Härmä V, Haavikko R, Virtanen J, Ahonen I, Schukov HP, Alakurtti S, Purev E, Rischer H, Yli-Kauhaluoma J, Moreira VM, et al: Optimization of Invasion-Specific Effects of Betulin Derivatives on Prostate Cancer Cells through Lead Development. PLoS One. 10:e01261112015. View Article : Google Scholar : PubMed/NCBI | |
|
Bai SW, Herrera-Abreu MT, Rohn JL, Racine V, Tajadura V, Suryavanshi N, Bechtel S, Wiemann S, Baum B and Ridley AJ: Identification and characterization of a set of conserved and new regulators of cytoskeletal organization, cell morphology and migration. BMC Biol. 9:542011. View Article : Google Scholar : PubMed/NCBI | |
|
Jackson SJ and Singletary KW: Sulforaphane: A naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization. Carcinogenesis. 25:219–227. 2004. View Article : Google Scholar |
